描述了基于环己-1,4-二烯的气态碘化氢替代品的设计和克级合成。通过用中等强度的布朗斯台德酸引发,碘化氢从替代物转移到 CC 多重键上,例如炔烃和丙二烯,而没有游离碘化氢的参与。代用品碎片化为甲苯和乙烯,易挥发废物。这种氢碘化反应避免了对碘化氢或氢碘酸的不稳定处理。通过这种方式,可以以立体控制的方式访问范围广泛的以前未知或难以制备的乙烯基碘。
A divergent approach to apoptolidin and FD-891: asymmetric preparation of a common intermediate
作者:Shu-Sin Chng、Jia Xu、Teck-Peng Loh
DOI:10.1016/s0040-4039(03)01173-0
日期:2003.6
Biologically active Apoptolidin and FD-891 have structural similarity in their macrocyclic cores. Asymmetric preparation of a common intermediate in the totalsynthesis of these two macrolides is presented. A modified Masuyama Sn-allylation was employed to control the relative stereochemistry in the synthesis of the intermediate.
Synthesis of substituted pyridines and pyridazines via ring closing metathesis
作者:Timothy J. Donohoe、Lisa P. Fishlock、José A. Basutto、John F. Bower、Panayiotis A. Procopiou、Amber L. Thompson
DOI:10.1039/b904363b
日期:——
RCM can be used to make aromatic heterocycles, namely pyridines and, for the first time, pyridazines; the key step after RCM involves elimination of sulfinate to provide the aromatic system.
Sequential sigmatropic rearrangements (Claisen/Claisen and Claisen/Overman) of enantiopure allylic diols are described. The reactions proceeded in complete diastereoselectivity without protecting group manipulations. The sequential Claisen/Overman rearrangement was successfully applied to the totalsynthesis of (−)-kainic acid.
Chirality Transfers through Sequential Sigmatropic Rearrangements of Allylic Vicinal Diols: Development and Application to Total Synthesis of (-)-Kainic Acid
sigmatropic rearrangements starting from enantiopure allylic vicinal diols. Starting from the same allylic diol, the sequential Claisen/Claisen rearrangement can install two identical functional groups in a one-pot reaction, whereas, the sequential Claisen/Overman rearrangement can introduce two different functional groups, both occurring without protecting group manipulation. Both sequential reactions proceeded
Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.